ZBNA
VRDN icon

Zions Bancorporation, National Association’s Viridian Therapeutics VRDN Stock Holding History

Zions Bancorporation, National Association’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36K Sell
74
-16
-18% -$258 ﹤0.01% 1372
2026
Q1 		$1.76K Buy
+90
New +$2.67K ﹤0.01% 1240

Other funds holding VRDN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Zions Bancorporation, National Association's VRDN Position: Q2 2026 in Review

Zions Bancorporation, National Association reduced its Viridian Therapeutics (VRDN) stake by 18% in Q2 2026, selling an estimated $258 and leaving 74 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #1372.

Zions Bancorporation, National Association first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.76K in Q1 2026. 31 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Zions Bancorporation, National Association held 74 shares of Viridian Therapeutics worth $1.36K as of Q2 2026.
  • Zions Bancorporation, National Association sold 16 Viridian Therapeutics shares in Q2 2026, an estimated $258.
  • Viridian Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1372 holding.
  • Zions Bancorporation, National Association first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Zions Bancorporation, National Association's Viridian Therapeutics position peaked at $1.76K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.